MedPath

Does buprenorphine 0.3 mg prolongs the analgesic effect of a blockade of the femoral nerve with ropivaciane 0.2% for patients with a total knee replacement. A prospective triple-blinded placebo-controlled RCT?

Phase 4
Withdrawn
Conditions
anaesthesie, pijnbehandeling
pain perception
total knee replacement.
Registration Number
NL-OMON37162
Lead Sponsor
Westfries Gasthuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
63
Inclusion Criteria

18-80 years.
Elective total knee replacement,

Exclusion Criteria

Fever, temperature higher than 37.5 degrees Celsius (orthopedic surgery don*t proceed)
Allergy to local anesthetics
Allergy to buprenorphine
pregnancy
Opiate use pre existent for surgery,
Infection of the skin at the area of the needle insertion opening in favor of Vagus femoralisblokkade.
Revision surgery of the knee.
General anesthesia instead of spinal anesthesia.
If patient is not under full anesthetic protocol policy for prosthetic hip and knee surgery.
EGFR <50 ml per minute.
Allergy to Non Steroid Anti Inflammatory Drugs (NSAIDS).
If pre-operative 10cm above the patella in the midline there is no left versus right difference in cold sensation than ithe block is tittled not sufficient and the patient will be removed from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Does 0.3 mg of buprenorphine as an additive in femoral nerve blockade prolongs<br /><br>analgesia?</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath